MUC1-gene-DC-CTL (Beijing Doing Biomedical)

N/A

Report date: 2022/11/02 16:12:51

Base Information

Drug NameMUC1-gene-DC-CTL (Beijing Doing Biomedical)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionMucin-1 modulatorsCytotoxic T lymphocytes replacements
TargetsMucin-1
Therapy Area/IndicationsStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Doing Biomedical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Doing Biomedical Co Ltd
Inactive CompaniesN/A
Active IndicationsStomach Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A